CA2659905A1 - Formulations phyto-oestrogeniques pour soulager ou prevenir des maladies neurodegeneratives - Google Patents

Formulations phyto-oestrogeniques pour soulager ou prevenir des maladies neurodegeneratives Download PDF

Info

Publication number
CA2659905A1
CA2659905A1 CA002659905A CA2659905A CA2659905A1 CA 2659905 A1 CA2659905 A1 CA 2659905A1 CA 002659905 A CA002659905 A CA 002659905A CA 2659905 A CA2659905 A CA 2659905A CA 2659905 A1 CA2659905 A1 CA 2659905A1
Authority
CA
Canada
Prior art keywords
estrogen
formulation
women
brain
selective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002659905A
Other languages
English (en)
Inventor
Roberta Diaz Brinton
Liqin Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2659905A1 publication Critical patent/CA2659905A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CA002659905A 2006-08-02 2007-07-13 Formulations phyto-oestrogeniques pour soulager ou prevenir des maladies neurodegeneratives Abandoned CA2659905A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US81984906P 2006-08-02 2006-08-02
US60/819,849 2006-08-02
US88992007P 2007-02-14 2007-02-14
US60/889,920 2007-02-14
US94319007P 2007-06-11 2007-06-11
US60/943,190 2007-06-11
PCT/US2007/073505 WO2008016768A1 (fr) 2006-08-02 2007-07-13 Formulations phyto-œstrogéniques pour soulager ou prévenir des maladies neurodégénératives

Publications (1)

Publication Number Publication Date
CA2659905A1 true CA2659905A1 (fr) 2008-02-07

Family

ID=38672818

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002659905A Abandoned CA2659905A1 (fr) 2006-08-02 2007-07-13 Formulations phyto-oestrogeniques pour soulager ou prevenir des maladies neurodegeneratives

Country Status (5)

Country Link
EP (1) EP2046325A1 (fr)
JP (1) JP2009545605A (fr)
AU (1) AU2007281381A1 (fr)
CA (1) CA2659905A1 (fr)
WO (1) WO2008016768A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
CN101641013B (zh) 2007-01-22 2014-07-30 Gtx公司 核受体结合剂
WO2013050930A1 (fr) * 2011-10-02 2013-04-11 Sinoveda Canada, Inc, Développement d'un produit de phytoestrogène de trèfle des prés pour la prévention ou le traitement de l'ostéoporose
US9333192B2 (en) 2010-02-15 2016-05-10 Sinoveda Canada, Inc Phytoestrogen product of red clover and pharmaceutical uses thereof
CA3032036A1 (fr) 2016-07-26 2018-02-01 Ausio Pharmaceuticals, Llc Methodes de diagnostic et de traitement de la maladie d'alzheimer par s-equol
WO2018049141A1 (fr) * 2016-09-12 2018-03-15 Steven Hoffman Compositions destinées au traitement de la démence
KR20220043857A (ko) * 2020-09-29 2022-04-05 주식회사 뉴로바이오넷 3-페닐-2h-크로멘 유도체 및 이를 함유하는 알츠하이머의 예방 또는 치료용 약학적 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2160371A1 (fr) * 1993-04-16 1994-10-27 The Trustees Of Tufts College Methode pour le traitement des symptomes menopausiques et premenstruels
NZ527735A (en) * 1997-05-01 2005-10-28 Novogen Inc Treatment or prevention of menopausal symptoms and osteoporosis
EP1163225A1 (fr) * 1999-03-17 2001-12-19 Signal Pharmaceuticals, Inc. Composes et techniques de modulation des recepteurs des oestrogenes
US20040072765A1 (en) * 1999-04-28 2004-04-15 Novogen Research Pty Ltd. Cardiovascular and bone treatment using isoflavones
AUPQ008399A0 (en) * 1999-04-28 1999-05-27 Novogen Research Pty Ltd Cariovascular applications
JP2004524289A (ja) * 2000-12-22 2004-08-12 アストラゼネカ・アクチエボラーグ 治療化合物
JP2006504409A (ja) * 2002-07-24 2006-02-09 チルドレンズ　ホスピタル　メディカル　センター 鏡像異性のエクオールを含有する組成物および製品、およびその製造方法
ES2559777T3 (es) * 2004-03-17 2016-02-15 Nestec S.A. Composiciones y métodos para reducir o prevenir la obesidad

Also Published As

Publication number Publication date
AU2007281381A1 (en) 2008-02-07
EP2046325A1 (fr) 2009-04-15
WO2008016768A1 (fr) 2008-02-07
WO2008016768A8 (fr) 2008-06-12
JP2009545605A (ja) 2009-12-24

Similar Documents

Publication Publication Date Title
US8552057B2 (en) Phytoestrogenic formulations for alleviation or prevention of neurodegenerative diseases
CA2659905A1 (fr) Formulations phyto-oestrogeniques pour soulager ou prevenir des maladies neurodegeneratives
US6524616B1 (en) Compositions and methods for treating or preventing neurodegeneration and cognitive decline and dysfunction associated with alzheimer's disease, aging, other dementia related disorders and estrogen deficiency related conditions
TWI258369B (en) Pharmaceutical compositions of a selective estrogen receptor modulator in combination with sex steroid precursors
Gennari et al. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development
Y Maximov et al. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice
Norbury et al. The neuroprotective effects of estrogen on the aging brain
US20040192598A1 (en) Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
Imhof et al. Effects of a red clover extract (MF11RCE) on endometrium and sex hormones in postmenopausal women
US20220323464A1 (en) Composition, formulations and methods of making and using botanicals and natural compounds for the promotion of healthy brain aging
TW201100403A (en) Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
Virojchaiwong et al. Comparison of Pueraria mirifica 25 and 50 mg for menopausal symptoms
JP2020520966A (ja) Ｔｒｐｖ１を標的にするミルセン及びカンナビノイド含有組成物
Papadopoulos et al. Leydig cell aging: Molecular mechanisms and treatments
US8680140B2 (en) Phytoestrogenic formulations for alleviation or prevention of menopausal symptoms
Miville-Godbout et al. Plasmalogen precursor mitigates striatal dopamine loss in MPTP mice
Wang et al. Recent advances in selective estrogen receptor modulators for breast cancer
Zhao et al. Estrogen receptor β as a therapeutic target for promoting neurogenesis and preventing neurodegeneration
AU2011236080A1 (en) Phytoestrogenic formulations and uses thereof
JP5569949B2 (ja) うつ病を治療するための、選択的セロトニン再取り込み阻害剤およびグルココルチコイド受容体拮抗薬を含む薬物組み合わせ
US20120269793A1 (en) Phytoestrogenic formulations for alleviation or prevention of hair loss
Zhao et al. ESTROGEN THERAPY FOR PREVENTING ALZHEIMER'S DISEASE: THERAPEUTIC STRATEGIES TO ADDRESS HORMONE THERAPY CHALLENGE FOR THE BRAIN
Ho The involvement of estrogen receptor (ER) and G protein-coupled estrogen receptor (GPR30) in rapid cellular signaling of phytoestrogens in osteoblasts
Landry et al. EFFECT OF ESTRADIOL AND SELECTIVE ESTROGEN RECEPTOR MODULATORS ON MEMBRANE DOPAMINE AND VESICULAR MONOAMINE TRANSPORTERS IN
Singh et al. 99 TESTOSTERONE MODULATES TRANSFORMING GROWTH FACTOR [beta] SIGNALING PATHWAY GENES IN MESENCHYMAL PLURIPOTENT C3H 10T1/2 STEM CELLS: IMPLICATIONS IN REGULATION OF BODY COMPOSITION.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20140715